Skip to main content
ENLV
NASDAQ Life Sciences

Enlivex Finalizes 1-for-15 Reverse Stock Split, Effective July 9th, to Address Nasdaq Compliance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.456
Mkt Cap
$123.441M
52W Low
$0.509
52W High
$2.1
52W Position info
10% below low
Off High info
78% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

ENLV is trading near its 52-week low of $0.509 (10% below the low).

Summary

Enlivex Ltd. announced a 1-for-15 reverse stock split, effective July 9, 2026, a critical step to meet Nasdaq's minimum bid price requirement after receiving a non-compliance notice.


Key Events · Corporate Governance and Compliance · ENLV

  • Reverse Split Finalized

    The Board of Directors approved a 1-for-15 reverse stock split, effective July 9, 2026, following shareholder authorization on February 3, 2026.

  • Nasdaq Compliance Action

    This action directly addresses a Nasdaq notice received on May 15, 2026, regarding the company's failure to meet the minimum $1.00 bid price requirement.

  • Share Structure Adjustment

    Outstanding shares will decrease from 252.5 million to approximately 16.8 million, with authorized shares also reduced proportionally. Fractional shares will be rounded up.

  • Trading Below 52-Week Low

    The company's stock is currently trading at $0.456, which is below its 52-week low of $0.5089, highlighting the urgency of the reverse split for listing compliance.


Analysis · ENLV · Life Sciences

Enlivex's decision to implement a 1-for-15 reverse stock split is a critical move to regain compliance with Nasdaq's minimum bid price requirement, following a notice received on May 15, 2026. This action, while necessary for continued listing, typically signals underlying challenges and is often viewed negatively by the market, especially as the stock is currently trading below its 52-week low. The split will drastically reduce the number of outstanding shares and increase the per-share price, but does not change the company's overall market valuation.

At the time of this filing, ENLV was trading at $0.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $123.4M. The 52-week trading range was $0.51 to $2.10. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ENLV - Latest Insights

ENLV
Aug 06, 2026, 4:43 PM EDT
Filing Type: F-3
Importance Score:
7
Price at Filing: $1.94
Real-time Price: $2.10 info
Change: +$0.1569 (+8%) info
Market Cap: $35.011M info
ENLV
Jul 30, 2026, 8:02 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.21
Real-time Price: $2.10 info
Change: -$0.1113 (-5%) info
Market Cap: $35.011M info
ENLV
Jul 28, 2026, 4:40 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $2.30
Real-time Price: $2.10 info
Change: -$0.1999 (-9%) info
Market Cap: $35.011M info
ENLV
Jul 28, 2026, 8:02 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.47
Real-time Price: $2.10 info
Change: -$1.37 (-39%) info
Market Cap: $35.011M info
ENLV
Jul 28, 2026, 8:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $3.47
Real-time Price: $2.10 info
Change: -$1.37 (-39%) info
Market Cap: $35.011M info